Q1 and Q2 saw monumental revenues. Could Q3 be even bigger for this biotech stock?

"BioStem is a company worth paying attention to," says Zack's SCR. This biotech stock may be headed for a NASDAQ uplisting very soon which could be a catalyst for more gains!

BioStem Technologies (OTC: BSEM) is a leading innovator focused on harnessing the natural properties of perinatal tissue in the development, manufacture, and commercialization of allografts for regenerative therapies. The Company is focused on manufacturing products that change lives, leveraging its proprietary BioREtain® processing method. BioREtain® has been developed by applying the latest research in regenerative medicine, focused on maintaining growth factors and preserving tissue structure. Both the diabetes wound care market and surgical recovery wound care market are growing at a tremendous rate and offer BSEM a big opportunity, especially because diabetes and issues from diabetes are increasing worldwide. A recent study confirmed that BSEM technology is superior and very helpful to patients. More doctors are turning to BioStem for treatments, resulting in increasing sales!

The medtech arena is not the easiest to navigate given how many kinds of companies are in it. It's all about finding emerging players that have successfully navigated the regulatory process (a real barrier to entry) and show real growth. BioStem Technologies, Inc. (OTC: BSEM) is growing fast in the medtech space, with record revenue and profitability in 2024! Third Quarter 2024 Financial Results Will be Released on Tuesday, November 12th! Could BSEM hit it out of the park again in Q3? Both Q1 and Q2 were blowout quarters for the company. With each successful quarter, Zacks Small Cap Research (SCR) upped its price target on shares! The last time Zacks SCR upped its price target was $24.25. Could another price target increase be on the way after BSEM report its third quarter results? The company has also filed with the SEC to register its shares pursuant to the Securities Exchange Act of 1934, which is an important step in its plan to uplist to the Nasdaq stock exchange!

See why a NASDAQ uplisting and possibly another strong financial quarter could trigger tremendous growth for BSEM!

This message is a paid advertisement for BioStem Technologies Inc. (OTC: BSEM) from Sideways Frequency and Huge Alerts. It's Today Media, LLC. receives a fixed fee for each subscriber that clicks on a link in this email, totaling up to $5,500.00. Other than the compensation received for this advertisement sent to subscribers, It's Today Media and its principals are not affiliated with either Sideways Frequency or Huge Alerts. It's Today Media and its principals do not own any of the stocks mentioned in this email or in the article that this email links to. Neither It's Today Media nor its principals are FINRA-registered broker-dealers or investment advisers. The content of this email should not be taken as advice, an endorsement, or a recommendation from It's Today Media to buy or sell any security. It's Today Media has not evaluated the accuracy of any claims made in this advertisement. It's Today Media recommends that investors do their own independent research and consult with a qualified investment professional before buying or selling any security. Investing is inherently risky. Past-performance is not indicative of future results. Please see the disclaimer regarding BioStem Technologies Inc. (OTC: BSEM) on Huge Alerts' website for additional information about the relationship between Huge Alerts and BioStem Technologies Inc. (OTC: BSEM) .